Vyleesi and Imaging Contrast Dye: What You Need to Know Before Your Scan

What bremelanotide actually is

Bremelanotide is a cyclic peptide that activates melanocortin receptors, most relevantly MC1R (found on melanocytes), MC3R, and MC4R (both involved in central nervous system pathways related to appetite and sexual response). It is sold under the brand name Vyleesi and is given as a single 1.75 mg subcutaneous injection, self-administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours. The FDA approved it in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women, under NDA 210557. [1]

Bremelanotide is not a GLP-1 receptor agonist, an appetite medication, or related to semaglutide or tirzepatide, despite occasional confusion online because melanocortin and incretin pathways both intersect with metabolic research. It is a distinct drug class with a distinct approved use.

Does Vyleesi actually interact with contrast dye?

This is the question the title promises to answer, and the honest answer is that the evidence for a specific, labeled "contrast dye interaction" is weaker than earlier versions of this kind of article have implied. Bremelanotide's own prescribing information describes transient focal hyperpigmentation as an adverse reaction, tied to MC1R activation and melanin synthesis in skin. [1] Separately, radiology literature establishes that melanin-containing tissue can behave differently on MRI, most notably in melanotic melanoma metastases, where melanin's paramagnetic properties produce T1 hyperintensity that can be mistaken for or overlap with contrast enhancement. [4] Those two facts are biologically related, since both involve melanin. They are not the same finding.

No source reviewed for this article documents that bremelanotide-induced transient hyperpigmentation has been shown to measurably interfere with the interpretation of a gadolinium-enhanced MRI or an iodinated-contrast CT scan in real patients. A specific quoted label instruction to "hold bremelanotide for at least 12 hours before any planned imaging procedure that uses a contrast agent" could not be verified against the sources available here. If that language exists in the current FDA label, it should be cited exactly and dated; if it does not, it should not be repeated as fact. Anyone relying on this article for a clinical decision should check the current Vyleesi prescribing information directly. [1]

Here is the compact version worth remembering: bremelanotide has no confirmed pharmacologic interaction with iodinated CT contrast or gadolinium-based MRI contrast. Its two labeled effects relevant to a same-day procedure are a transient blood pressure rise, lasting roughly the first half-day after dosing, and, less commonly, focal skin hyperpigmentation that can be long-lasting. Neither effect has documented evidence of altering how a contrast study is read. Patients should still disclose recent use so a blood pressure change at check-in is correctly attributed to the medication rather than mistaken for a new medical problem.

Iodinated CT contrast works by X-ray attenuation, a mechanism unrelated to melanin or paramagnetic signal, which is a further reason the mechanistic link to bremelanotide is weaker for CT than the melanin-MRI reasoning above. [5]

Evidence-status assessment: bremelanotide and imaging

What is established, what is plausible, and what is not

Established, from the FDA label and the RECONNECT trial program: bremelanotide can cause transient hyperpigmentation and a transient blood pressure rise, and it reduces naltrexone exposure when co-administered. [1][6]

Plausible but unproven: that visible skin pigmentation changes or the blood pressure effect could, in theory, complicate a clinical encounter around the time of imaging, since some imaging suites screen blood pressure and some scans involve the face or oral cavity. This is a reasonable precaution to mention to a care team, not a documented radiologic confound.

Not established: a specific interaction between bremelanotide and contrast media (iodinated or gadolinium-based) that changes image quality, interpretation, or safety. Nothing in the sources for this article demonstrates that outcome.

Blood pressure and procedural check-ins

Bremelanotide's prescribing information describes a transient increase in blood pressure after dosing that resolves within hours, part of why the label advises against use in women with known cardiovascular disease. [1] Many imaging suites and procedure areas check blood pressure before contrast administration. A patient who dosed Vyleesi shortly before arriving for a scan could show an elevated reading that has nothing to do with the reason for the scan. Mentioning recent bremelanotide use to the imaging team avoids that confusion and lets staff decide, using their own protocols, whether to reschedule or proceed.

Does alcohol change how Vyleesi behaves?

Bremelanotide is not metabolized by the liver enzymes most associated with alcohol interactions, so there is no known pharmacokinetic interaction between the two. [1] The concern, if there is one, is pharmacodynamic: alcohol can lower blood pressure, and bremelanotide can too, at least transiently. Combining them within the same window could plausibly produce more pronounced lightheadedness or hypotension, particularly in someone already on blood pressure medication, though this combination has not been studied directly in a dedicated interaction trial. [7] The FDA label does not list alcohol as contraindicated. Treat this as a reasonable caution rather than a documented rule.

Naltrexone and other medication interactions

The one pharmacokinetic drug interaction described in bremelanotide's labeling involves naltrexone: co-administration reduces naltrexone exposure. [1] This matters because naltrexone is used to treat alcohol use disorder and opioid use disorder, and reduced exposure could undermine its intended effect. Anyone taking naltrexone for either indication should discuss bremelanotide use with the prescriber managing that treatment rather than assuming the two can be combined without a plan.

Because bremelanotide frequently causes nausea, oral medications taken around the same time may absorb less reliably if vomiting occurs. This is a general absorption concern rather than a specific studied interaction, and it is most relevant for medications with a narrow margin between an effective and an ineffective dose, such as certain anticonvulsants or thyroid replacement therapy. If vomiting occurs soon after taking another oral medication, contact the prescriber of that medication rather than guessing whether the dose still worked.

What to tell your radiology team and prescriber

Bremelanotide is used as needed rather than daily, so it will not necessarily show up on a standard medication list unless you mention it. A simple disclosure covers the points that matter:

"I use Vyleesi (bremelanotide) as needed. My last dose was [time]. It can cause a temporary blood pressure change and, less often, temporary skin darkening. I wanted your team to know in case it affects today's visit."

This framing is honest about what is documented (blood pressure effect, skin pigmentation) without asserting a specific imaging rule that could not be confirmed. If your imaging center has its own policy about recent bremelanotide use, follow that policy; it may be more conservative than anything stated here.

A short verification checklist

1. Tell the imaging or procedure team that you use Vyleesi, including your last dose time.
2. If you have cardiovascular disease or uncontrolled hypertension, discuss bremelanotide use with your prescriber before your next dose, independent of any imaging.
3. If you take naltrexone, confirm with that prescriber how to sequence the two medications.
4. If a specific "hold time before imaging" is quoted to you as an FDA requirement, ask to see the exact label language rather than accepting a secondhand paraphrase, including this one.

Regulatory and research context

Bremelanotide has not been approved by the European Medicines Agency as of this writing; regulatory status can change, so this should be checked against the EMA's current medicines database before being restated as a fixed fact. [8] A 2021 clinical practice guideline from the International Society for the Study of Women's Sexual Health addresses systemic testosterone for HSDD in women; it does not address bremelanotide's imaging profile specifically, so it does not resolve the question this article set out to answer. [9]

Melanocortin receptor biology remains an active research area beyond bremelanotide, including work on MC4R variants and metabolic regulation, as described in genetics research and early investigational work on molecular imaging tracers that target melanocortin receptors directly, mostly in melanoma research, though a verifiable source for this specific work was not available for this article. That is a different application from contrast-enhanced CT or MRI in a Vyleesi user, and it should not be read as evidence that today's routine imaging is affected by bremelanotide use.

This article is drafted for editorial and qualified medical review and has not yet received that review. The specific claim about a labeled contrast-imaging hold time could not be verified from the sources available during drafting; a reviewer with direct access to the current FDA label should confirm or remove it before publication.